Last October Novo Nordisk announced that it ... An oral version of insulin would be an enormous breakthrough in treating type 1 and type 2 diabetes patients, as freedom from daily injections ...

Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...

Novo Nordisk has developed semaglutide, a drug based on GLP-1 receptor activation, which increases pancreatic insulin release ...